BGMD — BG Medicine Share Price
Last trade - 00:00- $0.00m
- -$1.52m
- $1.57m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -485.83% | ||
| Return on Equity | -1184.34% | ||
| Operating Margin | -295.66% | ||
Financial Summary
| Year End 31st Dec | Unit | 2011 | 2012 | 2013 | 2014 | 2015 | 2016E | 2017E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.63 | 2.81 | 4.07 | 2.79 | 1.57 | n/a | n/a | 13.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The Company's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Directors
- Harry Wilcox CHM
- Paul Sohmer PRE (67)
- Stephen Hall CFO (65)
- Aram Adourian SVP (46)
- Jeffrey Luber IND (49)
- James O'Connor IND (71)
- Stelios Papadopoulos IND (72)
- Last Annual
- December 31st, 2015
- Last Interim
- December 31st, 2015
- Incorporated
- February 9th, 2000
- Public Since
- February 4th, 2011
- No. of Shareholders
- 27
- No. of Employees
- 5
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 11,374,360
- Address
- 880 Winter Street, Suite 210, WALTHAM, 02451
- Web
- Phone
- +1 7818901199
- Auditors
- Marcum LLP
Upcoming Events for BGMD
Similar to BGMD
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 19:33 UTC, shares in BG Medicine are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in BG Medicine last closed at $0.00 and the price had moved by +9900% over the past 365 days. In terms of relative price strength the BG Medicine share price has outperformed the S&P500 Index by +9242.66% over the past year.
There is no consensus recommendation for this security.
Find out moreBG Medicine does not currently pay a dividend.
BG Medicine does not currently pay a dividend.
BG Medicine does not currently pay a dividend.
To buy shares in BG Medicine you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in BG Medicine had a market capitalisation of $0.00m.
Here are the trading details for BG Medicine:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BGMD
Based on an overall assessment of its quality, value and momentum BG Medicine is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BG Medicine. Over the past six months, its share price has outperformed the S&P500 Index by +10251.48%.
As of the last closing price of $0.00, shares in BG Medicine were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BG Medicine PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BG Medicine's management team is headed by:
- Harry Wilcox - CHM
- Paul Sohmer - PRE
- Stephen Hall - CFO
- Aram Adourian - SVP
- Jeffrey Luber - IND
- James O'Connor - IND
- Stelios Papadopoulos - IND